In-Depth Analysis of Besremi, Jakafi, and Rusfertide in Polycythemia Vera Treatment

 


Polycythemia Vera Treatment Landscape

Jakafi (Ruxolitinib), developed by Incyte, is an FDA-approved drug for the treatment of Polycythemia Vera. Jakafi is a JAK1/JAK2 inhibitor that works by reducing the overactive signaling of JAK1 and JAK2, which are associated with the symptoms of Polycythemia Vera. Jakafi’s patent expiration date is in 2027, but several companies have filed for generics. However, there might be a delay in the entry of generics due to legal disputes.

PharmaEssentia’s new entrant, entry into NCCN guidelines, insights on pricing, and launches

Besremi (Ropeginterferon alfa-2b) is a new entrant in the Polycythemia Vera market, developed by PharmaEssentia. It is a subcutaneous injection and has a different mode of action than Jakafi. Besremi is an interferon alpha-2b derivative that regulates the immune system and bone marrow, which can help control the overproduction of blood cells in Polycythemia Vera. Besremi was approved in the EU in 2020 and received FDA approval in the US in 2021. It has also been included in the National Comprehensive Cancer Network (NCCN) guidelines for the treatment of Polycythemia Vera. The pricing of Besremi is yet to be revealed, and the launch is expected in 2021.

Protagonist therapeutics’ Rusfertide: Uncertainty in uptake even with promising results?

Rusfertide (PTG-300) is an investigational drug developed by Protagonist Therapeutics for the treatment of Polycythemia Vera. Rusfertide is a hepcidin mimetic that regulates iron metabolism and controls erythropoiesis, which could help treat anemia in Polycythemia Vera. Rusfertide has shown promising results in clinical trials, and Protagonist has plans for its commercialization. However, the drug recently faced a setback as the FDA withdrew its Breakthrough Therapy Designation (BTD) due to concerns about the design of ongoing clinical trials. The uncertainty about Rusfertide’s approval could affect its uptake in the Polycythemia Vera market.


In conclusion, the Polycythemia Vera market has seen some significant developments in recent years, with the approval of new drugs like Besremi and investigational drugs like Rusfertide. The entry of generics for Jakafi might face some legal disputes, which could delay their launch. The pricing of Besremi is yet to be revealed, and its launch is expected soon. The uncertainty about the approval of Rusfertide could affect its uptake in the Polycythemia Vera market. However, with the availability of new drugs and emerging therapies in Polycythemia Vera, the Polycythemia Vera market is expected to grow in the coming years.

Related Reports

B Cell Chronic Lymphocytic Leukemia Market

DelveInsight's "B Cell Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Chronic Lymphocytic Leukemia, historical and forecasted epidemiology as well as the B Cell Chronic Lymphocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


B-Cell Lymphomas Market

DelveInsight's "B-Cell Lymphomas Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Lymphomas, historical and forecasted epidemiology as well as the B-Cell Lymphomas market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Behcet’s Syndrome Market 

DelveInsight’s “Behcet’s Syndrome Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Behcet’s syndrome in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom.


Neoantigen-based Personalized Cancer therapeutic Vaccines 

DelveInsight’s “Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035” report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Glioblastoma Multiforme Market

DelveInsight's "Glioblastoma Multiforme Market Insights, Epidemiology and Market Forecast– 2032" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.


Latest Reports By DelveInsight

Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market


To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting

Recent Blog’s By DelveInsight:

Comments

Post a Comment

Popular posts from this blog

The Great PD-1 Inhibitor Battle: OPDIVO vs. KEYTRUDA in Japan

Image
  Analyzing OPDIVO’s Pre-2022 Sales Decline and KEYTRUDA’s Market Ascendancy Before 2022, OPDIVO, developed by Bristol-Myers Squibb (BMS), faced a significant sales decline in Japan’s PD-1 inhibitor market. Despite its initial success, the PD-1 and PD-L1 inhibitors faced challenges from new competitors and evolving market dynamics. One key competitor was Merck's KEYTRUDA, which steadily gained market share due to its broader range of approved indications and successful clinical trial outcomes. KEYTRUDA’s market ascendancy was marked by its approval for various cancers, including melanoma, non-small cell lung cancer, and urothelial carcinoma, among others, making it a versatile choice for oncologists. How OPDIVO Outpaced KEYTRUDA in Japan’s Pharmaceutical Market In 2022, OPDIVO made a remarkable comeback, outpacing KEYTRUDA in Japan’s pharmaceutical market. This resurgence was driven by several strategic moves by BMS. The company expanded OPDIVO’s indications, securing approvals fo
Read more

A detailed analysis of Vascular Stents Market Trends, Growth Opportunities, Challenges, and Epidemiology Forecast

Image
A vascular surgeon places a stent, which is a hollow mesh tube that supports the blood vessel's walls permanently and prevents it from closing up again (restenosis). Some stents are drug-eluting, which means they release medicine over time to help prevent another blockage. The  Vascular Stents market is being driven by a growing geriatric population as well as an increase in the number of surgical operations. The  Vascular Stents Market report from DelveInsight provides an in-depth analysis of  Vascular Stents, as well as historical and forecasted market trends in the 7MM (the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some Key Highlights from the  Vascular Stents Market Report The artery is kept open by a stent, which is a small metal mesh tube. The two methods for opening clogged peripheral arteries are angioplasty and stent implantation. Vascular Stents market is segmented on the basis of Product type, By Applications and End-user. Some of the
Read more
Image
Obstructive Sleep Apnea Market Trends and Therapeutic Advancements !! Obstructive Sleep Apnea (OSA) is a common chronic sleep disorder, which is characterized by periodic narrowing and obstruction of the pharyngeal airway during sleep, leading to a complete or partial obstruction of the airway, results of which are apneas, hypopneas, or sometimes both. Obstructive sleep apnea is a chronic and permanent condition, through proper therapy and medications the condition can be cured. Almost every system in the body is affected by Obstructive Sleep Apnea, resulting in an increased incidence of hypertension, stroke, altered immune system, and cardiovascular disease.  Obstructive Sleep Apnea is caused when the throat muscles relax during sleep, which causes the tissue in the back of the throat to collapse and block the upper airway. Daytime sleepiness is one of the most common symptoms of Obstructive Sleep Apnea. People affected with Obstructive Apnea also complain of memory problems, headach
Read more